bio rad dctm protein assay kit (Bio-Rad)
Bio-Rad is a verified supplier 
Bio-Rad manufactures this product 
97
Structured Review
Bio-Rad
bio rad dctm protein assay kit
Bio Rad Dctm Protein Assay Kit, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 97/100, based on 16891 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctm+protein+assay+reagents/DC+Protein+Assay+Reagents+Package/pm41895991-141-9-15
Average 97 stars, based on 16891 article reviews
Bio Rad Dctm Protein Assay Kit, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 97/100, based on 16891 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctm+protein+assay+reagents/DC+Protein+Assay+Reagents+Package/pm41895991-141-9-15
Average 97 stars, based on 16891 article reviews
bio rad dctm protein assay kit - by Bioz Stars,
2026-09
97/100 stars
Images
Related Articles
Spectrophotometry:Article Title: Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value. Article Snippet: Purpose To determine the cyclin-dependent kinase 12 (CDK12) expression in chordoma patient tissues and cell lines, its correlation with oncologic outcomes, and its function in chordoma cell proliferation.. Methods A chordoma tissue microarray was constructed from fifty-six patient specimens and examined by immunohistochemistry to measure CDK12 expression and its correlation to patient clinical characteristics and survival.. CDK12 expression in chordoma cell lines and patient tissues was evaluated via western blot. Article Title: CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma. Article Snippet: Osteosarcoma (OS) is a bone malignant tumor affecting children, adolescents, and young adults.. Currently, osteosarcoma is treated with chemotherapy regimens established over 40 years ago.. The investigation of novel therapeutic strategies for the treatment of osteosarcoma remains an important clinical need. Article Title: Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma. Article Snippet: While amplified expressed cyclin E1 is a well-known tumorigenic factor and prognostic biomarker in several malignancies, its prognostic predictive potential and function in osteosarcoma is poorly understood.. Here we reveal discrete expression pattern, correlation to clinicopathological characteristics and prognosis and overall function of cyclin E1 in osteosarcoma.. Sixty-nine osteosarcoma patient tumor specimens were enrolled to construct a tissue microarray to evaluate cyclin E1 expression through immunohistochemical staining. Article Title: Expression and Clinical Significance of High‐Mobility Group AT‐hook 2 ( HMGA2 ) in Osteosarcoma Article Snippet: Protein lysates from the osteosarcoma cells and tissues were extracted using 1× RIPA lysis buffer (Sigma‐Aldrich) and protease inhibitor cocktail tablets (Roche Applied Science, IN, USA). .. The protein concentrations were then calculated by the Article Title: Establishment and Characterization of a Novel Dedifferentiated Chondrosarcoma Cell Line DDCS2 Article Snippet: We extracted protein lysates with 1×RIPA lysis buffer (Upstate Biotechnology, US) containing complete protease inhibitor cocktail tablets (Roche Applied Science, US). .. Concentrations were determined using Article Title: Expression and Clinical Significance of High-Mobility Group AT-hook 2 (HMGA2) in Osteosarcoma. Article Snippet: Methods: Sixty-nine osteosarcoma patient specimens within a tissue microarray (TMA) were analyzed by immunohistochemistry for HMGA2 expression.. Demographics and clinicopathological information including age, gender, tumor location, metastasis, recurrence, chemotherapy response, follow-up time, and disease status were also collected.. After validation of expression, we determined whether there was a correlation between HMGA2 expression and patient clinicopathology. Article Title: T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma Article Snippet: The protein was extracted from cells and osteosarcoma tissue specimens by 1× RIPA lysis buffer (Sigma‐Aldrich) supplemented with protease inhibitor cocktail tablets (Roche Applied Science, Indianapolis, IN, USA). .. The concentrations of protein lysate were then evaluated by Lysis:Article Title: Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer. Article Snippet: .. Protein lysates were prepared using the |